AI Generated Image
FDA clears Bristol multiple myeloma therapy, marking debut of new drug class
STAT • • business
Key Points:
- The FDA approved iberdomide, an oral treatment for advanced multiple myeloma developed by Bristol Myers Squibb, introducing a new class of medicine for the blood cancer.
- Iberdomide, branded as Zenbexus, will be used in combination with Darzalex and dexamethasone for patients who have undergone at least one prior therapy.
- This approval marks the first time U.S. regulators have cleared a drug using a more sensitive measure of remission.
- Bristol Myers Squibb is the first company to bring this novel class of drugs to multiple myeloma patients, potentially enabling more combination treatment options.
